Publication/Presentation Date

10-29-2020

Abstract

In recent years, the role of immune checkpoint inhibitors (ICI) in cancer treatment has rapidly expanded. In randomized clinical trials, these agents have demonstrated clinical efficacy in extending survival and increasing response rates. Immune-related adverse effects (irAEs) involving various organs have been frequently narrated. Herein, we present a case report of thrombotic thrombocytopenic purpura (TTP) as a rare side effect of nivolumab, plus ipilimumab, in the treatment of metastatic renal cell carcinoma (RCC). A review of the literature for other case reports of TTP during treatment with ICIs was also performed. Our aim is to elucidate the significance of early recognition of this rare adverse effect in patients being treated with this relatively newer class of medications.

Volume

12

Issue

10

First Page

11246

Last Page

11246

ISSN

2168-8184

Disciplines

Oncology

PubMedID

33274128

Department(s)

Hematology-Medical Oncology Division

Document Type

Article

Included in

Oncology Commons

Share

COinS